公司概覽
業務類別 Diagnostics & Research
業務概覽 Idexx Laboratories primarily develops, manufactures, and distributes diagnostic products, equipment, and services for pets and livestock. Its key product lines include single-use canine and feline test kits that veterinarians can employ inthe office, benchtop chemistry and hematology analyzers for test-panel analysis on-site, reference lab services, and tests to detect and manage disease in livestock. The firm also offers vet practice management software and consulting services to animal hospitals. Idexx derives roughly 35% of its revenue from outside the United States.
公司地址 One IDEXX Drive, Westbrook, ME, USA, 04092
電話號碼 +1 207 556-0300
傳真號碼 +1 207 556-4346
公司網頁 https://www.idexx.com
員工數量 11000
 
公司高管 / 董事會成員
公司高管
高管 職務 年薪 更新日期
Dr. Michael G. Erickson, PhD Executive Vice President and General Manager, Point of Care Diagnostics and Telemedicine -- 13/01/2026
Mr. Andrew J. Emerson Executive Vice President, Chief Financial Officer, Treasurer and Principal Accounting Officer 美元 531.15K 27/03/2026
Mr. George J. Fennell Executive Vice President, Global CAG Commercial -- 27/03/2026
Mr. Jonathan J. Mazelsky Director, President and Chief Executive Officer 美元 1.15M 13/01/2026
Dr. Martin Alexander Smith, PhD Executive Vice President, Global Operations and Research and Development 美元 594.05K 27/03/2026
Ms. Sharon E. Underberg Executive Vice President, General Counsel and Corporate Secretary -- 27/03/2026
Mr. Michael J. Lane Executive Vice President and General Manager, Global Reference Laboratories, Diagnostic Solutions and Information Technology 美元 594.05K 27/03/2026
Mr. Michael Schreck Executive Vice President and General Manager, Veterinary Software and Services, Corporate Accounts and Customer Experience -- 27/03/2026
Mr. Michael P. Johnson Senior Vice President and Chief Human Resources Officer -- 27/03/2026
 
董事會成員
董事會 職務 更新日期
Mr. Bruce L. Claflin Independent Director 27/03/2026
Mr. Daniel M. Junius Independent Director 27/03/2026
Ms. M. Anne Szostak Independent Director 13/02/2026
Mr. Lawrence D. Kingsley Non-Executive Chairman of the Board 27/03/2026
Dr. Sophie V. Vandebroek, PhD Independent Director 27/03/2026
Mr. Stuart M. Essig, PhD Independent Director 27/03/2026
Mr. Jonathan J. Mazelsky Director, President and Chief Executive Officer 13/01/2026
Mr. Sam A. Samad Independent Director 27/03/2026
Mr. Joseph L. Hooley Lead Independent Director 27/03/2026
Ms. Karen A. Peacock Independent Director 27/03/2026
Ms. Irene Chang Britt Independent Director 27/03/2026
 
所屬ETF (更新日期: 02/05/2026 04:29)
代號 名稱 佔比% 持有日期
XCHGAB US Equity ETF0.0002%29/04/2026
ONOFGlobal X Adaptive US Risk Management ETF0.0002%29/04/2026
ESGGFlexShares STOXX Glbl ESG Select ETF0.0002%29/04/2026
EBILongview Advantage ETF0.0002%29/04/2026
MMTMState Street® SPDR® S&P® 1500MomtTiltETF0.0002%29/04/2026
PFUTPutnam Sustainable Future ETF0.0002%31/03/2026
LCOWPacer S&P 500 Qul FCF Aristocrats ETF0.0002%29/04/2026
TPLETimothy Plan US Large/Mid Cp Cr Enh ETF0.0002%02/10/2025
ESLGEventide Large Cap Growth ETF0.0002%29/04/2026
NVIRHorizon Kinetics Energy Remediation ETF0.0002%29/04/2026
ACVFAmerican Conservative Values ETF0.0001%29/04/2026
RILAIndexperts Gorilla Aggressive Growth ETF0.0001%29/04/2026
SPXNProShares S&P 500® ex-Financials0.0001%29/04/2026
QARPXtrackers Russell 1000 US QARP ETF0.0001%29/04/2026
URSPProShares Ultra S&P 500 Equal Weight0.0001%28/02/2026
SPXEProShares S&P 500® ex-Energy0.0001%29/04/2026
SPGMState Street® SPDR® Ptf MSCIGlbStkMktETF0.0001%27/04/2026
XOEFiShares S&P 500 ex S&P 100 ETF0.0001%29/04/2026
XYLGGlobal X S&P 500® Covered Call & Gr ETF0.0001%29/04/2026
QEWInvesco QQQ Equal Weight ETF0.0001%29/04/2026
  1    2    3    4    5    6    7    8    9    10    11    12    13   14    15    16    17    18    19  
 

Copyright © 2026 ET Net Limited.
All rights reserved. Use of this site signifies your agreement to the terms of use.
DISCLAIMER: ET Net Limited and Third Party Information Providers endeavour to ensure the accuracy and reliability of the information provided, but do not guarantee its accuracy and reliability and accept no liability (whether in tort or contract or otherwise) for any loss or damage arising from any inaccuracies or omissions.